1-(1-Methyl-4-piperidinyl)-1-butanone | 1160994-48-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-(1-Methyl-4-piperidinyl)-1-butanone
• 英文别名: 1-(1-methylpiperidin-4-yl)butan-1-one
• CAS: 1160994-48-8
• 化学式: C₁₀H₁₉NO
• mdl: MFCD12400746
• 分子量: 169.26
• InChiKey: PJMVHEKASFTSAU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• ISOTHIAZOLOPYRIDINE-2-CARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS
  申请人：Sanofi

  公开号：US20140296169A1

  公开（公告）日：2014-10-02

  The present disclosure relates to substituted isothiazolo[5,4-b]pyridine-2-carboxamides of the formula I, in which R1, R2, R3, R10, R11 and X are as defined in the claims. The compounds of the formula I are inhibitors of transglutaminases, in particular transglutaminase 2 (TGM2), and are suitable for the treatment of various diseases, for example degenerative joint diseases such as osteoarthritis. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

  本公开涉及公式I的取代异噻唑并[5,4-b]吡啶-2-羧酰胺，其中R1、R2、R3、R10、R11和X如索赔中所定义。公式I的化合物是转谷氨酰胺酶抑制剂，特别是转谷氨酰胺酶2（TGM2）的抑制剂，并适用于治疗各种疾病，例如退行性关节疾病如骨关节炎。本发明还涉及公式I化合物的制备方法，它们作为药物的用途，以及包含它们的药物组合物。
• Bis(thio-hydrazide amide) compounds in combination with taxol for treating cancer
  申请人：Synta Pharmaceuticals Corporation

  公开号：EP2100605A1

  公开（公告）日：2009-09-16

  There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein Y, Z and R1 to R6 have meanings given in the description, for use in the treatment of melanoma or renal cancer by administration of said compound, in the same or separate pharmaceutical composition, with paclitaxel or a paclitaxel analog. There is also provided the use of a compound of formula (I) for the production of a medicament for administration, in the same or separate pharmaceutical composition, with paclitaxel or a paclitaxel analog, for treating melanoma or renal cancer.

  本发明提供了一种式 (I) 的化合物： 或其药学上可接受的盐，其中 Y、Z 和 R1 至 R6 具有描述中给出的含义，用于通过在相同或单独的药物组合物中与紫杉醇或紫杉醇类似物一起施用所述化合物来治疗黑色素瘤或肾癌。还提供了式(I)化合物用于生产治疗黑色素瘤或肾癌的药物，在相同或单独的药物组合物中，与紫杉醇或紫杉醇类似物一起给药。
• Bis(thio-hydrazide amide) salts for treatment of cancers
  申请人：Synta Pharmaceuticals Corp.

  公开号：EP2305642A2

  公开（公告）日：2011-04-06

  Disclosed are bis(thio-hydrazide amide) disalts, which are represented by Structural Formula (I)          2 M+ or M2+Y is a covalent bond or a substituted or unsubstituted straight chained hydrocarbyl group. R1-R4 are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R2 and R4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. Z is -O or -S. M+ is a pharmaceutically acceptable monovalent cation and M2+ is a pharmaceutically acceptable divalent cation. Also disclosed are pharmaceutical compositions comprising a bis(thio-hydrazide amide) disalt described above. Further disclosed are methods of treating a subject with cancer. The methods comprise the step of administering an effective amount of a bis(thio-hydrazide amide) disalt.

  所公开的是双(硫代酰肼酰胺)二盐，其结构式为 (I) 2 M+ 或 M2+Y 是共价键或取代或未取代的直链烃基。R1-R4 独立地为-H、脂肪族基团、取代的脂肪族基团、芳基或取代的芳基，或 R1 和 R3 与它们所键合的碳原子和氮原子，和/或 R2 和 R4 与它们所键合的碳原子和氮原子，形成一个可选择与芳香环融合的非芳香杂环。Z 是-O 或-S。M+ 是药学上可接受的一价阳离子，M2+ 是药学上可接受的二价阳离子。还公开了包含上述双（硫肼酰胺）二盐的药物组合物。进一步公开了治疗癌症患者的方法。这些方法包括给药有效量的双(硫代酰肼酰胺)二盐的步骤。
• Combination with Bis(thiohydrazide amides) for treating cancer
  申请人：Koya Keizo

  公开号：US20080119440A1

  公开（公告）日：2008-05-22

  Disclosed herein are methods of treating a proliferative disease, such as cancer, with bis(thio-hydrazide amides) or a tautomer, pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, in combination with hyperthermia treatment. Also disclosed are methods of treating a proliferative disease, such as cancer, with bis(thio-hydrazide amides) or a tautomer, pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, in combination with radiotherapy.
• Treating melanoma with BIS(THIOHYDRAZIDE AMIDES)
  申请人：Williams Martin

  公开号：US20080176828A1

  公开（公告）日：2008-07-24

  Disclosed herein are methods of preventing or delaying the recurrence of melanoma in a subject with bis(thio-hydrazide amides) represented by a formula selected from Structural Formulas (I)-(IX) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these bis(thio-hydrazide amides) and compositions comprising these bis(thiohydrazide)amides and one or more anti-cancer agent.